Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Boceprevir and telaprevir for the treatment of chronic hepatitis C: safety management in clinical practice.

Hézode C.

Liver Int. 2012 Feb;32 Suppl 1:32-8. doi: 10.1111/j.1478-3231.2011.02707.x. Review.

2.

Phase III results of Boceprevir in treatment naïve patients with chronic hepatitis C genotype 1.

Manns MP, Markova AA, Calle Serrano B, Cornberg M.

Liver Int. 2012 Feb;32 Suppl 1:27-31. doi: 10.1111/j.1478-3231.2011.02725.x. Review.

PMID:
22212568
3.

Triple therapy for HCV genotype 1 infection: telaprevir or boceprevir?

Shiffman ML, Esteban R.

Liver Int. 2012 Feb;32 Suppl 1:54-60. doi: 10.1111/j.1478-3231.2011.02718.x. Review.

PMID:
22212573
4.

Triple therapy with telaprevir: results in hepatitis C virus-genotype 1 infected relapsers and non-responders.

Forestier N, Zeuzem S.

Liver Int. 2012 Feb;32 Suppl 1:44-50. doi: 10.1111/j.1478-3231.2011.02720.x. Review.

PMID:
22212571
5.

Triple therapy with boceprevir for HCV genotype 1 infection: phase III results in relapsers and nonresponders.

Bacon BR, Khalid O.

Liver Int. 2012 Feb;32 Suppl 1:51-3. doi: 10.1111/j.1478-3231.2011.02700.x. Review.

PMID:
22212572
6.

Boceprevir for chronic HCV genotype 1 infection.

Limaye AR, Draganov PV, Cabrera R.

N Engl J Med. 2011 Jul 14;365(2):176; author reply 177-8. doi: 10.1056/NEJMc1105515#SA1. No abstract available.

PMID:
21751914
7.

UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients.

Ramachandran P, Fraser A, Agarwal K, Austin A, Brown A, Foster GR, Fox R, Hayes PC, Leen C, Mills PR, Mutimer DJ, Ryder SD, Dillon JF.

Aliment Pharmacol Ther. 2012 Mar;35(6):647-62. doi: 10.1111/j.1365-2036.2012.04992.x. Epub 2012 Feb 1.

8.

Telaprevir versus boceprevir in chronic hepatitis C: a meta-analysis of data from phase II and III trials.

Sitole M, Silva M, Spooner L, Comee MK, Malloy M.

Clin Ther. 2013 Feb;35(2):190-7. doi: 10.1016/j.clinthera.2012.12.017. Epub 2013 Jan 29.

PMID:
23369368
9.

Telaprevir for chronic hepatitis C virus infection.

Jesudian AB, Jacobson IM.

Clin Liver Dis. 2013 Feb;17(1):47-62. doi: 10.1016/j.cld.2012.09.010. Review.

PMID:
23177282
10.

Management of anaemia and other treatment complications.

Hézode C.

Dig Liver Dis. 2013 Sep 30;45 Suppl 5:S337-42. doi: 10.1016/j.dld.2013.07.010. Review.

PMID:
24091113
11.

Future treatment of patients with HCV cirrhosis.

Bourlière M, Khaloun A, Wartelle-Bladou C, Oules V, Portal I, Benali S, Adhoute X, Castellani P.

Liver Int. 2012 Feb;32 Suppl 1:113-9. doi: 10.1111/j.1478-3231.2011.02702.x. Review.

PMID:
22212581
12.

Early virologic responses and hematologic safety of direct-acting antiviral therapies in veterans with chronic hepatitis C.

Belperio PS, Hwang EW, Thomas IC, Mole LA, Cheung RC, Backus LI.

Clin Gastroenterol Hepatol. 2013 Aug;11(8):1021-7. doi: 10.1016/j.cgh.2013.03.006. Epub 2013 Mar 21.

PMID:
23524130
13.

Boceprevir and treatment of chronic hepatitis C.

Kwo PY.

Clin Liver Dis. 2013 Feb;17(1):63-72. doi: 10.1016/j.cld.2012.09.005. Review.

PMID:
23177283
14.

Optimal treatment with telaprevir for chronic HCV infection.

Jesudian AB, Jacobson IM.

Liver Int. 2013 Feb;33 Suppl 1:3-13. doi: 10.1111/liv.12079. Review.

PMID:
23286840
15.

[Use of boceprevir and telaprevir in patients with hepatitis C virus infection (practical considerations)].

Crespo G, Lens S.

Gastroenterol Hepatol. 2012 May;35(5):337-43. doi: 10.1016/j.gastrohep.2011.12.005. Epub 2012 Feb 19. Spanish.

PMID:
22349607
16.

Anemia management in patients with chronic viral hepatitis C.

Hynicka LM, Heil EL.

Ann Pharmacother. 2013 Feb;47(2):228-36. doi: 10.1345/aph.1R513. Epub 2013 Feb 5. Review.

PMID:
23386076
17.

Hepatitis C virus-human immunodeficiency virus coinfection.

Sulkowski MS.

Liver Int. 2012 Feb;32 Suppl 1:129-34. doi: 10.1111/j.1478-3231.2011.02719.x. Review.

PMID:
22212583
18.

Telaprevir for HIV/hepatitis C virus-coinfected patients failing treatment with pegylated interferon/ribavirin (ANRS HC26 TelapreVIH): an open-label, single-arm, phase 2 trial.

Cotte L, Braun J, Lascoux-Combe C, Vincent C, Valantin MA, Sogni P, Lacombe K, Neau D, Aumaitre H, Batisse D, de Truchis P, Gervais A, Michelet C, Morlat P, Vittecoq D, Rosa I, Bertucci I, Chevaliez S, Aboulker JP, Molina JM; French National Agency for Research on AIDS and Viral Hepatitis (ANRS) HC26 Study Group.

Clin Infect Dis. 2014 Dec 15;59(12):1768-76. doi: 10.1093/cid/ciu659. Epub 2014 Aug 18.

PMID:
25139963
19.

Optimal treatment with boceprevir for chronic HCV infection.

Maasoumy B, Manns MP.

Liver Int. 2013 Feb;33 Suppl 1:14-22. doi: 10.1111/liv.12070. Review.

PMID:
23286841
20.

Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow.

Asselah T, Marcellin P.

Liver Int. 2012 Feb;32 Suppl 1:88-102. doi: 10.1111/j.1478-3231.2011.02699.x. Review.

PMID:
22212578

Supplemental Content

Support Center